

#### **24 December 2019**

#### **Appendix 3B**

**NetLinkz Limited (ASX: NET) ('NetLinkz'** or **'Company'**) advises that a more detailed description of the transaction detailed in the attached Appendix 3b is available in Netlinkz Limited ASX Announcement dated 24 December 2019.

Robert Lees Company Secretary Mobile: +61 411 494 406 Email: rlees@netlinkz.com

\*\*\*ENDS\*\*\*

#### **About NetLinkz Limited**

NetLinkz provides secure and efficient cloud network solutions. The Company's technology makes Fortune-500 security commercially available for organisations of all sizes. NetLinkz has received numerous industry awards for its technology, including being a worldwide winner of the Global Security Challenge.

www.netlinkz.com

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/00, \ 30/o9/01, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12 \ \ o1/o1/o3, \ o1$ 

Name	of	entity	

NETLINKZ LIMITED

ABN

55 141 509 426

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued Convertible Notes ('Notes')

Number of \*securities issued or to be issued (if known) or maximum number which may be issued On conversion up to 25,000,000 shares 37,500,000 Options exercisable at \$0.20 expiring 23 Dec 2022

3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Terms as per Cleansing Notice dated 23 December 2019

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No – Convertible Notes do not rank equally with an existing class of quoted securities and do not confer on the note holder any right as a member or shareholder of the Company including voting rights.

Fully paid ordinary shares issued upon conversion of the Notes on the terms disclosed in cleansing Notice dated 23 December 2019 will rank in all respects equally with the Company's existing ordinary shares

5 Issue price or consideration

Aggregate face value of \$7,500,000

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Issued pursuant to funding agreement announced on 23 December 2019 and Cleansing Notice dated 23 December 2019

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and

No

6b The date the security holder resolution under rule 7.1A was passed

comply with section 6i

N/A

6c Number of \*securities issued without security holder approval under rule 7.1

Up to 25,000,000 shares 37,500,000 Options exercisable at \$0.20 expiring 23 Dec 2022

6d Number of \*securities issued with security holder approval under rule 7.1A

N/A

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1 – 164,3	90,953 shares
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	To be advised *	
			T
		Number	+Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	1,796,503,793* (* Up to)	Fully paid ordinary shares
		N l	+C1
_	N	Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the securities in section 2 if applicable)	39,375,000	Unlisted Options exercisable at \$0.01 expiring on 2 July 2020.
		33,500,000	Unlisted Options exercisable at \$0.045 expiring on 1 Aug 2020.

<sup>+</sup> See chapter 19 for defined terms.

1	
2,500,000	Unlisted Options exercisable at \$0.06 expiring on 1 Aug 2020.
5,000,000	Unlisted Options exercisable at \$0.12 expiring on 1 Aug 2020.
10,000,000	Unlisted Options exercisable at \$0.30 expiring on 1 Aug 2020.
267,379	Unlisted Options exercisable at \$0.187 on or before 3 November 2020.
188,890	Unlisted Options exercisable at \$0.045 expiring on 31 Jan 2020.
5,000,000	Unlisted Options exercisable at \$0.30 expiring on 31 Jan 2020.
3,300,000	Unlisted Options exercisable at \$0.06 expiring on 1 Jan 2021.
3,300,000	Unlisted Options exercisable at \$0.12 expiring on 1 Jan 2021.
3,400,000	Unlisted Options exercisable at \$0.24 expiring on 1 Jan 2021.
26,000,000	Unlisted Options exercisable at \$0.02

<sup>+</sup> See chapter 19 for defined terms.

	expiring on 2 Jul 2021.
2,250,000	Unlisted Options exercisable at \$0.045 expiring on 2 Jul 2021.
6,250,000	Unlisted Options exercisable at \$0.09 expiring on 2 Jul 2021.
5,000,000	Unlisted Options exercisable at \$0.15 expiring on 2 Jul 2021.
2,000,000	Unlisted Options exercisable at \$0.06 expiring on 1 Oct 2021.
2,000,000	Unlisted Options exercisable at \$0.12 expiring on 1 Oct 2021.
2,000,000	Unlisted Options exercisable at \$0.24 expiring on 1 Oct 2021.
2,000000	Unlisted Options exercisable at \$0.36 expiring on 1 Oct 2021.
25,000,000	Unlisted Options exercisable at \$0.02 expiring on 21 Dec 2021.
50,800,000	Unlisted Options exercisable at \$0.037 expiring on 31 Jan 2022.

<sup>+</sup> See chapter 19 for defined terms.

		37,500,000*	Unlisted Options exercisable at \$0.20 expiring on 23 Dec 2022. *
		2*	Convertible Notes
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part 2	? - Bonus issue or pro rat	a issue	
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A	
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations	N/A	
20	Names of any underwriters	N/A	

<sup>+</sup> See chapter 19 for defined terms.

21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A

<sup>+</sup> See chapter 19 for defined terms.

	B - Quotation of securities I only complete this section if you are applying for quotation of securities
34	Type of securities (tick one)
(a)	Securities described in Part 1. Fully paid ordinary shares only
(b)	All other securities
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entitie	s that have ticked box 34(a)
Additi	onal securities forming a new class of securities
Tick to docume	indicate you are providing the information or ents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000
	10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Entitie	s that have ticked box 34(b)
38	Number of securities for which  †quotation is sought
39	Class of *securities for which quotation is sought
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?
	If the additional securities do not rank equally, please state:

<sup>+</sup> See chapter 19 for defined terms.

	<ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	+Class

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be

<sup>+</sup> See chapter 19 for defined terms.

quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.

- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 24 December 2019

(Company Secretary)

Print name: Robert Lees

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,294,797,447	
Add the following:		
<ul> <li>Number of fully paid ordinary securities issued in that 12-month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities</li> </ul>	442,937,115	
issued in that 12-month period with shareholder approval		
<ul> <li>Number of partly paid ordinary securities that became fully paid in that 12-month period</li> </ul>		
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12-month period	-	
"A"	1,737,734,562	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	260,660,184	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<ul> <li>Insert number of equity securities issued or agreed to be issued in that 12-month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as</li> </ul>	33,769,231 Issued 12 December 2019  this Appendix 3B – Up to 25,000,000 shares 37,500,000 Options	
separate line items "C"	00 000 004	
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1		
"A" x 0.15  Note: number must be same as shown in Step 2	260,660,184	
Subtract "C"	96,269,231	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	164,390,953	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A" Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10 Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount 7.1A that has already been used	of placement capacity under rule
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	
Step 4: Subtract "E" from ["A" x " placement capacity under rule 7.1  "A" x 0.10  Note: number must be same as shown in Step 2	-
Subtract "E" Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E" Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.